ATE289318T1 - 17alfa, 21-dihydroxypregnene esters als antiandrogene wirkstoffe - Google Patents

17alfa, 21-dihydroxypregnene esters als antiandrogene wirkstoffe

Info

Publication number: ATE289318T1
Authority: AT; Austria
Prior art keywords: esters; antiandrogenic; dihydroxypregne; 17alfa; actives
Prior art date: 2001-08-10

Application number

AT02764767T

Other languages

English (en)

Inventor

Mauro Ajani

Luigi Moro

Original Assignee

Cosmo Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-10

Filing date

2002-07-24

Publication date

2005-03-15

2002-07-24 Application filed by Cosmo Spa filed Critical Cosmo Spa

2005-03-15 Application granted granted Critical

2005-03-15 Publication of ATE289318T1 publication Critical patent/ATE289318T1/de

Links

230000002280 anti-androgenic effect Effects 0.000 title abstract 2
238000000034 method Methods 0.000 abstract 2
WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 abstract 1
BCFCRXOJOFDUMZ-ONKRVSLGSA-N Anecortave Chemical compound O=C1CC[C@]2(C)C3=CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 BCFCRXOJOFDUMZ-ONKRVSLGSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Dispersion Chemistry (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT02764767T 2001-08-10 2002-07-24 17alfa, 21-dihydroxypregnene esters als antiandrogene wirkstoffe ATE289318T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT2001MI001762A ITMI20011762A1 (it)	2001-08-10	2001-08-10	Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione
PCT/EP2002/008226 WO2003014141A1 (en)	2001-08-10	2002-07-24	17alfa, 21-dihydroxypregnene esters as antiandrogenic agents

Publications (1)

Publication Number	Publication Date
ATE289318T1 true ATE289318T1 (de)	2005-03-15

Family

ID=11448271

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02764767T ATE289318T1 (de)	2001-08-10	2002-07-24	17alfa, 21-dihydroxypregnene esters als antiandrogene wirkstoffe

Country Status (14)

Country	Link
US (6)	US20050026889A1 (de)
EP (1)	EP1421099B1 (de)
JP (1)	JP4354809B2 (de)
KR (1)	KR100889595B1 (de)
CN (1)	CN1246328C (de)
AT (1)	ATE289318T1 (de)
AU (1)	AU2002328956B2 (de)
CA (1)	CA2454675C (de)
DE (1)	DE60203013T2 (de)
ES (1)	ES2238595T3 (de)
IT (1)	ITMI20011762A1 (de)
MX (1)	MXPA04001274A (de)
PT (1)	PT1421099E (de)
WO (1)	WO2003014141A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2880276A1 (fr) *	2005-01-05	2006-07-07	Lefebvre Dominique Caparros	Utilisation des anti-androgenes dans le traitement des comportements agressifs ou impulsifs induits par des maladies du systeme nerveux central
ITMI20051695A1 (it) *	2005-09-14	2007-03-15	Cosmo Spa	Uso di 17a-esteri c3-c10 del 9,11-deidrocortexolone cme agenti anti-gonadotropinici
JP5456669B2 (ja) *	2007-05-03	2014-04-02	エールユニヴァーシティ	局所活性「ソフト」抗アンドロゲン剤
ITMI20071616A1 (it)	2007-08-03	2009-02-04	Cosmo Spa	Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
AU2014233577B2 (en) *	2007-08-03	2016-03-03	Cassiopea S.P.A.	Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
DK2444092T3 (en) *	2008-05-28	2015-09-28	Reveragen Biopharma Inc	Non-hormonal steroidmodulatorer of NF-? B for the treatment of disease
EP2556083A4 (de)	2010-04-05	2013-12-04	Validus Biopharma Inc	Nichthormonale steroide modulatoren von nf-kappa-b zur krankheitsbehandlung
ITMI20132157A1 (it)	2013-12-20	2015-06-21	Cosmo Dermatos Srl	Cortexolone 17alfa-propionate for use in the treatment of skin wounds and/or atrophic skin disorders . cortexolone 17alfa-propionato per uso nel trattamento delle ferite della pelle e/o disordini atrofici della pelle.
EP3006453A1 (de)	2014-10-08	2016-04-13	Cosmo Technologies Ltd.	17alpha-Monoester und 17alpha,21-Diester von Cortodoxon zur Verwendung bei der Behandlung von Tumoren
US10676723B2 (en) *	2015-05-11	2020-06-09	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
EP3108879A1 (de) *	2015-06-25	2016-12-28	Cassiopea S.p.A.	Hochkonzentrierte formulierung
WO2017004205A1 (en)	2015-06-29	2017-01-05	Reveragen Biopharma, Inc.	NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE
US11382922B2 (en)	2019-03-07	2022-07-12	Reveragen Biopharma, Inc.	Aqueous oral pharmaceutical suspension compositions
IT202100008429A1 (it) *	2021-04-06	2022-10-06	Farmabios Spa	Processo per la preparazione di cortexolone 17α-propionato e sua nuova forma cristallina idrata
WO2023088308A1 (zh) *	2021-11-16	2023-05-25	石家庄迪斯凯威医药科技有限公司	一种具有抗耐药性的抗菌化合物
CN115073546A (zh) *	2022-06-01	2022-09-20	浙江神洲药业有限公司	一种新型雄激素受体抑制剂的制备方法
TW202444338A (zh)	2023-04-07	2024-11-16	義大利商卡斯歐皮亞股份公司	克拉司酮與米諾地爾之組合療法
EP4529925A1 (de)	2023-09-26	2025-04-02	Cassiopea S.p.A.	Cortexolon-17-alpha-propionat zur behandlung von akneiformen erupten
CN121969376A (zh)	2023-09-26	2026-05-01	卡斯欧皮亚公司	用于治疗痤疮样皮疹的皮甾酮-17α-丙酸酯
AU2024399617A1 (en)	2023-12-14	2026-06-25	Cassiopea S.P.A.	Cortexolone-17αlpha-propionate combinations for treating acne
WO2025172818A1 (en)	2024-02-14	2025-08-21	Cassiopea S.P.A.	Pyrilutamide combination therapy
WO2026057588A1 (en)	2024-09-10	2026-03-19	Cassiopea S.P.A.	Clascoterone and minoxidil combination therapy for use in treating hair loss
WO2026087531A1 (en)	2024-10-22	2026-04-30	Cassiopea S.P.A.	Clascoterone formulations and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2985650A (en)	1958-05-28	1961-05-23	Syntex Sa	6alpha-ammonio-derivatives of 11-keto cortical hormones
CH429716A (de) *	1961-06-24	1967-02-15	Vismara Francesco Spa	Verfahren zur Herstellung von 17a-Acyloxy-21-hydroxy-Steroiden
NL6605514A (de) *	1966-04-25	1967-10-26
NL6605515A (de)	1966-04-25	1967-10-26
US3780177A (en) *	1967-06-16	1973-12-18	Warner Lambert Co	17-butyrate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use
JPS5910799B2 (ja)	1975-07-15	1984-03-12	大正製薬株式会社	プレグナン系ステロイド１７−エステル類の製法
DE3243482A1 (de)	1982-11-22	1984-05-24	Schering AG, 1000 Berlin und 4709 Bergkamen	Neue 6(alpha)-methylkortikoide, ihre herstellung und verwendung
DE3402330A1 (de)	1984-01-20	1985-07-25	Schering AG, 1000 Berlin und 4709 Bergkamen	1(alpha),2(alpha)-methylen-6-methylen- und 6(alpha)-methyl-pregnene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US5264428A (en) *	1990-02-16	1993-11-23	Kanoldt Arzneimittel Gmbh	Use of stigmasta-4-en-3-one in the treatment of androgen dependent diseases
JPH08135789A (ja)	1994-11-09	1996-05-31	Komatsu Ltd	車両の油圧式駆動装置の変速装置およびその変速制御方法
DE19653730C2 (de)	1996-12-11	1999-06-24	Schering Ag	Immobilisierte Proteine aus Rohextrakt und deren Verwendung zur Umsetzung von Estern
DE60209704T2 (de)	2001-05-22	2006-11-16	Pfizer Products Inc., Groton	Neue kristallforme von azithromycin
ATE338763T1 (de)	2002-08-02	2006-09-15	Schering Ag	Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie

2001
- 2001-08-10 IT IT2001MI001762A patent/ITMI20011762A1/it unknown
2002
- 2002-07-24 MX MXPA04001274A patent/MXPA04001274A/es active IP Right Grant
- 2002-07-24 US US10/486,386 patent/US20050026889A1/en not_active Abandoned
- 2002-07-24 KR KR1020047002060A patent/KR100889595B1/ko not_active Expired - Lifetime
- 2002-07-24 EP EP02764767A patent/EP1421099B1/de not_active Expired - Lifetime
- 2002-07-24 CA CA002454675A patent/CA2454675C/en not_active Expired - Lifetime
- 2002-07-24 DE DE60203013T patent/DE60203013T2/de not_active Expired - Lifetime
- 2002-07-24 WO PCT/EP2002/008226 patent/WO2003014141A1/en not_active Ceased
- 2002-07-24 ES ES02764767T patent/ES2238595T3/es not_active Expired - Lifetime
- 2002-07-24 JP JP2003519090A patent/JP4354809B2/ja not_active Expired - Lifetime
- 2002-07-24 AT AT02764767T patent/ATE289318T1/de active
- 2002-07-24 AU AU2002328956A patent/AU2002328956B2/en not_active Expired
- 2002-07-24 CN CNB028157192A patent/CN1246328C/zh not_active Expired - Lifetime
- 2002-07-24 PT PT02764767T patent/PT1421099E/pt unknown
2009
- 2009-06-24 US US12/457,870 patent/US8143240B2/en not_active Expired - Lifetime
2012
- 2012-02-16 US US13/398,222 patent/US20120149671A1/en not_active Abandoned
2013
- 2013-12-11 US US14/103,707 patent/US8865690B2/en not_active Expired - Lifetime
2014
- 2014-09-02 US US14/474,765 patent/US9211295B2/en not_active Expired - Lifetime
2015
- 2015-10-16 US US14/885,488 patent/US9895379B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE60203013T2 (de)	2006-02-09
US20120149671A1 (en)	2012-06-14
PT1421099E (pt)	2005-05-31
US20050026889A1 (en)	2005-02-03
EP1421099A1 (de)	2004-05-26
ITMI20011762A1 (it)	2003-02-10
JP4354809B2 (ja)	2009-10-28
CN1541220A (zh)	2004-10-27
KR100889595B1 (ko)	2009-03-20
US9211295B2 (en)	2015-12-15
AU2002328956B2 (en)	2007-08-16
JP2005504762A (ja)	2005-02-17
MXPA04001274A (es)	2005-06-06
US20150216878A1 (en)	2015-08-06
KR20040023748A (ko)	2004-03-18
EP1421099B1 (de)	2005-02-16
WO2003014141A1 (en)	2003-02-20
US20090264396A1 (en)	2009-10-22
CN1246328C (zh)	2006-03-22
US8865690B2 (en)	2014-10-21
CA2454675C (en)	2009-05-26
US20160263127A1 (en)	2016-09-15
US20140154306A1 (en)	2014-06-05
DE60203013D1 (de)	2005-03-24
ITMI20011762A0 (it)	2001-08-10
US9895379B2 (en)	2018-02-20
CA2454675A1 (en)	2003-02-20
ES2238595T3 (es)	2005-09-01
US8143240B2 (en)	2012-03-27

Legal Events

Date

Code

Title

Description

2005-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1421099

Country of ref document: EP

Publication	Publication Date	Title
DE60203013D1 (de)	2005-03-24	17alfa, 21-dihydroxypregnene esters als antiandrogene wirkstoffe
AU2002356759A1 (en)	2003-06-17	17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
DE69904804D1 (de)	2003-02-13	Glucocorticoid selektive entzündungshemmende mittel
PT1053240E (pt)	2003-09-30	Agentes anti-inflamatorios selectivos para glucocorticoides
BR0112160A (pt)	2003-10-07	Agentes antiinflamatórios seletivos para glicocorticóides
WO1999062510A3 (en)	2000-04-06	Compositions comprising anti-microtubule agents for treating or preventing inflammatory diseases
DE69523622D1 (de)	2001-12-06	Diastereomerenreine 3-oxo und 3-thioxo-4-aza-androstanderivate und ihre verwendung als antiandrogene
DE60017878D1 (de)	2005-03-10	Kombinationspräparate zur behandlung von erkrankungen, die mit angiogenese verbunden sind
AU4179399A (en)	1999-11-16	Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
BR0308660A (pt)	2005-01-25	C-17 espirolactonização e 6,7 oxidação de esteróides
ATE277609T1 (de)	2004-10-15	Glucocorticoid selektive entzündungshemmende mittel
BG103060A (bg)	1999-10-29	19- нор- холан стероиди като неврохимични инициатори на промяната в действието на хипоталамуса причовек
ATE160573T1 (de)	1997-12-15	1,3.5 (10) - estratriene derivate mit oraler wirkung
DE60327946D1 (de)	2009-07-23	Angiogen-wirkende trisulfat steroide und deren verwendung
NO20031444L (no)	2003-05-28	17<alfa>-fluoralkylsteroider, fremgangsmåte for fremstilling av disse, og farmasöytiske preparater som inneholder disse forbindelser
AU2003285485A1 (en)	2004-03-03	5 ANDROSTEN-3Beta-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION
DK1196428T3 (da)	2005-01-24	11-beta-aryl-17,17-spirothiolan-substituerede steroider
PT1165595E (pt)	2003-08-29	Derivados de acidos biliares especificos do figado provenientes do antagonista do glicocorticoide ru486
NZ505085A (en)	2002-10-25	Pharmaceutical compositions comprising bipapcitide monocarboxylate and/or bipapcitide dicarboxylate for imaging and treating thrombi
MXPA03011751A (es)	2004-07-01	Proceso para preparar 21-acetato de 11b,17a, 21-trihidroxi-6a-metilpregna-1, 4-dieno-3, 20- diona.
TW200603812A (en)	2006-02-01	D-homo-17-chlor-16(17)-ene steroids
UA34148A (uk)	2001-02-15	Спосіб прогнозування перебігу гіпертонічної хвороби